20 completed. 20 Phase 2, 6 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 20 |
| Phase 3 | 6 | Completed 6 |
| Phase 1 | 2 | Completed 2 |
Follow Rabeprazole: new trials by email Literature Review of Rabeprazole trials Research Report on Rabeprazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors BMS-986408, Nivolumab, Ipilimumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 68 | 2022-08-02 | 2026-08-13 |
| Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants TNP-2198, Rabeprazole Sodium, Amoxicillin - Helicobacter Pylori Infection | Phase 2 | Completed | TenNor Therapeutics (Suzhou) Limited | 80 | 2022-06-26 | 2023-12-12 |
| A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules TNP-2198, Rabeprazole Sodium, Amoxicillin - Helicobacter Pylori Infection | Phase 1 / Phase 2 | Completed | TenNor Therapeutics (Suzhou) Limited | 40 | 2021-09-27 | 2023-11-22 |
| A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers. Anaprazole Sodium, Rabeprazole sodium - Duodenal Ulcer，DU | Phase 2 | Completed | Sihuan Pharmaceutical Holdings Group Ltd. | 150 | 2018-10-09 | 2020-08-07 |
| Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy lucitanib 15 mg QD, lucitanib 10 mg QD, placebo QD - Advanced Thymic Carcinoma | Phase 2 | Completed | Haihe Biopharma Co., Ltd. | 74 | 2018-08-16 | 2026-09-17 |
| To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis Z-215 10mg, Z-215 20mg, Z-215 Placebo - Esophagitis, Reflux | Phase 2 | Completed | Zeria Pharmaceutical | 503 | 2015-05-01 | 2017-07-02 |
| Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) Rabeprazole - Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 405 | 2011-12-01 | 2015-12-21 |
| Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) E3810, Teprenone - Gastric or Duodenal Ulcers Caused by Low-dose Aspirin | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 472 | 2011-07-01 | 2014-11-26 |
| New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study Rabeprazole and Amoxicillin, Amoxicillin and Rabeprazole - Functional Dyspepsia | Phase 2 | Completed | Shanghai Jiao Tong University School of Medicine | 40 | 2011-04-01 | 2012-01-20 |
| A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810) Rabeprazole sodium, 5 mg Tablets, Rabeprazole sodium, 10 mg Tablets, Rabeprazole sodium, 20 mg Tablets - Healthy | Phase 2 | Completed | Eisai Co., Ltd. | 24 | 2010-09-01 | 2012-11-30 |
| Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects Omeprazole, Rabeprazole, Lactose - Gastroesophageal Reflux | Phase 2 | Completed | Nantes University Hospital | 2010-04-01 | 2026-09-14 | |
| A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204) Rabeprazole, Placebo - Functional Dyspepsia | Phase 2 | Completed | Eisai Co., Ltd. | 338 | 2010-04-01 | 2013-12-24 |
| Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis E3810 - Refractory Reflux Esophagitis | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 337 | 2008-10-01 | 2012-04-18 |
| Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients 5 mg ilaprazole, 10 mg ilaprazole, 10 mg Rabeprazole - Duodenal Ulcer | Phase 2 / Phase 3 | Completed | Livzon Pharmaceutical Group Inc. | 408 | 2008-08-01 | 2016-07-28 |
| Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant - Gastroesophageal Reflux Disease | Phase 2 / Phase 3 | Completed | US Department of Veterans Affairs | 236 | 2006-04-01 | 2014-08-18 |
| Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole rabeprazole sodium - Gastroesophageal Reflux Disease | Phase 2 | Completed | Eisai Inc. | 111 | 2005-08-01 | 2009-12-03 |
| Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD) Rabeprazole - Esophageal Reflux | Phase 2 | Completed | University of Kansas | 24 | 2005-05-01 | 2009-05-08 |
| Maintenance Intermittent Therapy for Symptomatic GERD Patients Rabeprazole 20 mg - Gastroesophageal Reflux Disease | Phase 2 | Completed | Eisai Inc. | 200 | 2004-10-01 | 2013-05-20 |
| Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment Aciphex - Laryngopharyngeal Reflux | Phase 2 / Phase 3 | Completed | University of Utah | 24 | 2003-08-01 | 2008-01-16 |
| Post-nasal Drainage as an Extraesophageal Manifestation of Reflux Rabeprazole 20 mg twice a day for 90-day period treatment - Postnasal Drainage | Phase 2 | Completed | Medical College of Wisconsin | 50 | 2002-06-01 | 2017-01-30 |
Gastroesophageal Reflux (6) · Duodenal Ulcer (3) · Esophagitis, Peptic (2) · Stomach Ulcer (2) · Dyspepsia (1) · Esophagitis (1) · Heartburn (1) · Laryngopharyngeal Reflux (1) · Neoplasms (1) · Pain (1) · Thymoma (1)
Eisai Co., Ltd. (5) · Eisai Inc. (2) · TenNor Therapeutics (Suzhou) Limited (2) · Bristol-Myers Squibb (1) · Haihe Biopharma Co., Ltd. (1) · Livzon Pharmaceutical Group Inc. (1) · Medical College of Wisconsin (1) · Nantes University Hospital (1) · Shanghai Jiao Tong University School of Medicine (1) · Sihuan Pharmaceutical Holdings Group Ltd. (1) · US Department of Veterans Affairs (1) · University of Kansas (1) · University of Utah (1) · Zeria Pharmaceutical (1)
United States (7) · Japan (6) · China (5) · France (2) · Canada (1) · Spain (1) · Switzerland (1)
Nobuyuki Sugisaki (2) · Yufang Lu (2) · Huiming Cai, MD (1) · Jerzy Sarosiek, PhD (1) · Li X B, M.D., Ph.D. (1) · Masahiro Munesue (1) · Mojtaba S. Olyaee, MD (1) · Susan Thibeault, Ph.D. (1) · Todd A Loehrl, MD (1) · Tomoki Kubota (1) · Yoshiumi Okubo (1)
PMID 38359854, PMID 17721405, PMID 20132154, PMID 22108775, PMID 23957383, PMID 25027286, PMID 34336894, PMID 38910891